Katharine Phillips, MD: Various Treatments for Obsessive-Compulsive Disorders
Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.
Read More
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”
Katharine Phillips, MD: Differences Between OCD, Body Dysmorphic Disorder
In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.
Brian Barnett, MD: Psychedelics Fitting into the SUDs Treatment Paradigm
In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.
Lenard A. Adler, MD: “Symptoms of ADHD Need to Go Back to Childhood”
In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
In an interview with HCPLive, Karlin and Robinson discuss the phase 2b trial on MM120 for generalized anxiety disorder.
Daniel Karlin, MD: Prevalence of Undiagnosed Generalized Anxiety Disorder
In an interview with HCPLive, Karlin discussed the unmet need for GAD screening.
The Future of DSM-5-TR with Nitin Gogtay, MD, Maria Oquendo, MD, PhD, and Jonathan Alpert, MD, PhD
At APA 2024, HCPLive interviewed APA members about how DSM-5-TR classifies psychiatric disorders differently than previous iterations.
Paul Appelbaum, MD: What to Warn Patients When Prescribing Psychedelics in the Future
In an interview, Paul Appelbaum, MD, discussed issues clinicians will need to bring up to their patients if the FDA approves a psychedelic-assisted therapy.
Ryan McLaughlin, PhD: Challenges Studying Cannabis to Treat Psychiatric Illness
In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.
Patient on Esketamine had Improved Depression, Fibromyalgia
Treatment-resistant depression with intranasal esketamine was linked to improvements in major depressive disorder (MDD) symptoms and fibromyalgia pain in a 40-year-old female.
Andrew Chen, MD: Taking More Adverse Event Prone Anxiety Medications
In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.
Andrew Chen, MD: Breaking Down First-Line Treatments, or Alternatives, for Anxiety
In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.
Physical Fitness Linked to All Gait Parameters for Women with Fibromyalgia
Cardiorespiratory fitness showed the strongest association with gait parameters for women with fibromyalgia.
Compositive Dietary Antioxidant Index Linked to endometriosis-related RA
A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.
Patients with new AS, PSA, RA Diagnosis Have High Reliance on Opioids
Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.
Sociodemographic Factors Linked to Topical Psoriasis Treatment Non-Adherence
A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.
Sleep Month in Review: April 2024
This sleep month in review features positive pipeline updates and treatments for improved sleep quality.
Psychiatry Month in Review: April 2024
This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.
Addressing Stigma to Improve Outcomes in Alcohol-Related Liver Disease
The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.
Demographic Factors Influence Medicine Adherence, Satisfaction for RA Treatment
Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.
FDA Issues a CRL for Ketamine’s Abbreviated New Drug Application
FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.
Brief Mindfulness Intervention for Psoriasis Boosts Awareness, Not Skin Health
A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.
Advancing Brilaroxazine Research in Schizophrenia with Larry Ereshefsky, PharmD
In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.
Connecting with Other Parents May Ease Parental Loneliness for Many
Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily lives.
Larry Ereshefsky, PharmD: Brilaroxazine Improves Schizophrenia Symptoms
Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.
FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.
Pediatric Study Reveals Link Between Skin Disorder Visibility and Stigma
The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.
Antihypertensive Medication Linked to Fracture Risk Among Older Adults
The fracture risk is greater for nursing home residents with dementia, greater baseline blood pressure values, and no recent antihypertensive medication use, a new study found.
Sleep of Psoriasis Patients Improves with Intensive Topical Treatment
A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.